LZLi‐Na Zhang

Li‐Na Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Li‐Na Zhang has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Jia-Jie Chen

    Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China

    1 shared publication
  • Kunmei Ji

    Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences Shenzhen University Medical School, Shenzhen University Shenzhen China

    1 shared publication
  • Yi‐Bo Hou

    Department of Biochemistry and Molecular Biology, School of Medicine, Shenzhen University, Shenzhen, China

    1 shared publication
  • Yuetong Sun

    Biotherapy Centre, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

    1 shared publication

Latest Publications

  • Aurora kinase inhibitor tozasertib suppresses mast cell activation in vitro and in vivo

    by Li‐Na Zhang, Kunmei Ji, Yue‐Tong Sun, Yi‐Bo Hou, Jia‐Jie Chen

    Background and Purpose Mast cells (MCs) are important in allergic reactions. Here, we assess the anti‐allergic effects of the anti‐cancer drug tozasertib specifically regarding regulatory effects on MCs activation. Experimental Approach Tozasertib effects on MC degranulation was determined by measuring β‐hexosaminidase and histamine release and by assessing morphological changes in RBL‐2H3 and mouse bone marrow‐derived mast cells (BMMCs) stimulated with mouse anti‐dinitrophenyl (DNP)‐immunoglobulin E (IgE)/DNP‐human serum albumin (HSA) or human LAD2 cells activated with phorbol‐12‐myristate 13‐acetate plus calcium ionophore (PMACI). Western blots were performed to detect the expression of molecules involved in NF‐κB, MAPK, and aurora kinase signaling. In vivo anti‐allergic effects of tozasertib were determined in the murine IgE‐mediated passive cutaneous anaphylaxis (PCA) and ovalbumin‐induced active systemic anaphylaxis (ASA) models. Key Results Tozasertib treatment resulted in significantly decreased high‐affinity IgE receptor (FcεRI) or PMACI‐mediated degranulation in RBL‐2H3 cells and in BMMCs or LAD2 cells as evidenced by β‐hexosaminidase or histamine levels. Similarly, tozasertib prevented morphological changes in MCs, such as particle release and F‐actin reorganization. In addition, tozasertib diminished the expression levels of phosphorylated (p)‐NF‐κB p65, p‐Erk1/2, p‐p38 and p‐Aurora A/B markedly, indicating that tozasertib can inhibit the signaling pathway mediating MC activation. Tozasertib attenuated IgE/Ag‐induced PCA dose‐dependently, as evidenced by reduced Evans blue staining. Similarly, tozasertib reduced body temperature levels and serum histamine levels in OVA‐challenged ASA mice. Conclusion and Implications The aurora kinase inhibitor tozasertib suppressed MC activation in vitro and in vivo. Tozasertib may be a potential drug for targeting MC activation to treat allergic diseases or mastocytosis.